Amyloidosis and Cancer Theranostics Program
The history of the Amyloidosis and Cancer Theranostics Program (ACTP) is rooted in the study of light chain (AL) amyloidosis and the development of novel agents for the study, detection and treatment of this disease. In recent years, the Program has both extended its horizons to encompass all amyloid-related disorders and some specific malignancies, and focused principally on peptides as biological agents for targeting these diseases as a means of detection and treatment. The major thrust of the ACTP is developing, characterizing and translating novel synthetic peptides into the clinic for the non-invasive imaging of amyloidosis in patients by using PET/CT and SPECT/CT. In addition, we are developing novel strategies for the treatment of amyloidosis by exploiting the exquisite targeting abilities of the synthetic peptides.
Preclinical and Diagnostic Molecular Imaging Laboratory
The Preclinical and Diagnostic Molecular Imaging Laboratory (PDMIL) is a small animal imaging facility dedicated to the study of disease and the development and evaluation of novel treatments and diagnostic techniques. The aim of the laboratory is to facilitate the translation of novel therapies and diagnostic agents into patients by providing proof-of-principle data in animal models of disease, as required by the US Food and Drug Administration. The laboratory focuses on research into amyloid-associated disorders, cancer, atherosclerosis and diagnostic veterinary imaging.
High quality clinical research enhances both the clinical and educational mission of our Department. As we strive to lead in healthcare delivery; we recognize the important role of clinical research in improving the quality of health care in our community and the world. Our clinical research department is dedicated to conducting clinical trials and research studies to further the translation of scientific knowledge into better health outcomes. Our research trials are carefully monitored tests to determine the effectiveness of medical therapies, medications and devices. We are currently conducting clinical trials in the areas of pulmonary medicine, infectious disease, hematology, oncology, cardiology and muscle weakness. For more information about our clinical trials please contact us at JFerris@utmck.edu or phone 865-305-7975.
Investigators in the Department of Medicine received over $3M in grants and contracts in 2013
Our faculty presented at the International Symposium on Amyloidosis
2013: Our faculty have 41 papers published in peer-reviewed journals
2012: Our faculty published more than 39 papers in peer-reviewed journals
2013: Our faculty wrote four book chapters and recorded two lectures for Audio Digest
2013: Four Residents presented posters at the National American College of Physicians Scientific Program
Professor Jonathan Wall Receives $1.58 Million Grant for Amyloid Disease Research
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2016